On the other hand, if data comes back and things play out the way everyone expects, in a few weeks the offering might be only 15million shares, or 10m, or possibly 5m... if the FDA isn't impressed with the results or slow-plays (again), then being on the NYSE won't mean so much, I don't think... that cash would be better used to ramp up production. JMO.

All uplisting will do is allow DIRECT institutional investment and give the SP a bump... I'm happy to buy every week at $3 so I'm in no rush for competition the likes of Goldman Sacs, etc.